magnesium-orotate and Magnesium-Deficiency

To make a meta-analysis of clinical trials of magnerot (magnesium orotate) used in cardiac patients.. The meta-analysis covered the data of 19 randomized trials including a total of 603 patients treated with magnerot (a case group) and 587 receiving placebo (a control group). The patients' mean age was 36 ± 19 years. On the average, the patients took magnerot 1878 ± 823 mg/day for 4.2 ± 29 months.. Associations between the intake of magnerot and the risk of 50 pathological conditions were analyzed. Significant associations were established between the drug's administration and the reduced risk of conditions, such as hypomagnesemia (relative risk (RR) = 0.06; 95% confidence intervals (C): 0.04 to 0.09; p = 2 · 10(-46)), exercise intolerance (RR = 0.41; 95% CI: 0.27 to 0.62; p = 0.0004), dysautonomia (RR = 0.08; 95% CI: 0.04 to 0.14; p = 2 · 10(-21)), morning headache (RR = 0.16; 95% CI: 0.09 to 0.29; p = 1.5-10(-6)), tension headache (RR = 0.16; 95% Cl: 0.09 to 0.27; p = 5 · 10(-10)), dizziness (RR = 0.28; 95% CI: 0.15 to 0.50; p = 0.0004), first-degree mitral valve prolapse (MVP) (RR = 0.05; 95% CI: 0.03 to 0.09; p = 1.2 · 10(-25)), grade 1 regurgitation (RR = 0.29; 95 CI: 0.14 to 0.60; p = 0.0075), supraventricular (RR = 0.30; 95% CI: 0.21 to 0.44; p = 1 · 10(-8)) and ventricular (RR = 0.48; 95% CI: 0.30 to 0.76; p = 0.019) premature contraction, paroxysmal supraventricular tachycardia (RR = 0.28; 95% CI: 0.15 to 0.50; p = 0.0002), and hypertension (RR = 0.32; 95% CI: 0.17 to 0.58; p = 0.0027).. The use of magnesium orotate is promising not only in treating MVP and compensating for hypomagnesemia, but also in preventing and treating cardiac arrhythmias, regulating blood pressure, and improving the function of the autonomic nervous system.. Цель исследования. Метаанализ клинических исследований применения препарата магнерот (оротат магния) в кардиологической практике. Материалы и методы. В метаанализ вошли данные 19 рандомизированных исследований, включившие суммарно 603 пациентов в группе 'случай' (прием магнерота) и 587 - в группе 'контроль' (плацебо). Средний возраст пациентов составил 36±19 лет. Пациенты принимали магнерот в среднем по 1878±823 мг/сут в течение 4,2±29 мес. Результаты. По данным проведенного анализа ассоциаций между приемом магнерота и риском развития 50 патологических состояний установлены достоверные ассоциации между приемом препарата и снижением риска возникновения таких состояний, как гипомагниемия - относительный риск (ОР) составил 0,06 при 95% доверительных интервалах (ДИ) от 0,04 до 0,09, р=2∙10–46, а также непереносимость физической нагрузки (ОР 0,41 при 95% ДИ от 0,27 до 0,62; р=0,0004), синдром вегетативной дистонии (ОР 0,08 при 95% ДИ от 0,04 до 0,14; р=2∙10–21), головная боль по утрам (ОР 0,16 при 95% ДИ от 0,09 до 0,29; р=1,5∙10–6), головная боль напряжения (ОР 0,16 при 95% ДИ от 0,09 до 0,27; р=5∙10–10), головокружения (ОР 0,28 при 95% ДИ от 0,15 до 0,50; р=0,0004), пролапс митрального клапана (ПМК) I степени (ОР 0,05 при 95% ДИ от 0,03 до 0,09; р=1,2∙10–25), регургитация I степени (ОР 0,29 при 95% ДИ от 0,14 до 0,60; р=0,0075), наджелудочковые (ОР 0,30 при 95% ДИ от 0,21 до 0,44; р=1∙10–8) и желудочковые экстрасистолы (ОР 0,48 при 95% ДИ от 0,30 до 0,76; р=0,019), пароксизмальная наджелудочковая тахикардия (ОР 0,28 при 95% ДИ от 0,15 до 0,50; р=0,0002) и гипертония (ОР 0,32 при 95% ДИ от 0,17 до 0,58; р=0,0027). Заключение. Использование оротата магния перспективно не только для терапии ПМК и компенсации гипомагниемии, но и для профилактики и лечения нарушений ритма сердца, регуляции артериального давления и улучшения функционирования вегетативной нервной системы.

Topics: Cardiovascular System; Evidence-Based Medicine; Humans; Magnesium Deficiency; Orotic Acid; Randomized Controlled Trials as Topic

Magnesium orotate dihydrate (MO) has the sum formula C10H6MgN4O8 x 2H2O and a MG of 370.52. The salt is poorly soluble in water and hence does not bind gastric acid nor does it exhibit noteworthy laxative effects upon oral administration in contrast to easily dissociable Mg salts. As a source of magnesium (Mg), MO is indicated for the oral treatment of extracellular Mg deficiency. Orotic acid (OA), the second active ingredient of MO, is a key intermediate in the biosynthetic pathway of pyrimidines and is shown to improve the energy status of injured myocardium by stimulating, a.o., the synthesis of glycogen and ATP. Myocardial energy-rich phosphate levels are decreased during hypoxic conditions; subsequently, intracellular Mg is depleted and lost via the urine. Since binding sites for Mg (ATP) are provided by OA it can be classified as "Mg-fixing agent". Accordingly MO is also indicated for the treatment of Mg depletion as convincingly shown in animal experiments and also in coronary heart patients undergoing e.g. aortocoronary bypass surgery.

Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Biological Availability; Clinical Trials as Topic; Heart; Heart Diseases; Heart Failure; Humans; Hyperlipidemias; Hypertension; Magnesium Deficiency; Orotic Acid

To assess efficiency of magnerot, magnesium orotate, in patients with idiopathic mitral prolapse (IMP).. 84 patients with IMP were randomized to the study group (43 patients) and control group (41 patients). Patients of the study group received magnerot tablets (Germany) containing 500 mg of magnesium orotate (daily dose 3000 mg) for 6 months. The examination performed before the treatment and 6 months after it included: modified clinical and phenotypic records, echocardiography, 24-h ECG and AP monitoring, spectral analysis of cardiac rhythm variability, evaluation of quality of life according to Visual Analog Scale and Disability Scale and of treatment results according to Clinical Global Impression scales, measurements of magnesium in the hair by plasmic nuclear emission spectrometry, histological and histochemical skin tests.. IMP patients appeared to suffer from magnesium deficiency which is responsible for many symptoms in mitral prolapse. 6-month therapy with magnerot completely or partially reduced the symptoms in more than half the patients. Positive changes were registered primarily in clinicofunctional manifestations. Morphological changes in the skin correlating with the disease severity alleviated.. Good objective and subjective response to magnerot 6-month therapy (3000 mg/day) is demonstrated.

Topics: Adult; Anticholesteremic Agents; Data Interpretation, Statistical; Echocardiography; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Magnesium Deficiency; Male; Mitral Valve Prolapse; Orotic Acid; Time Factors

Topics: Humans; Infant; Magnesium Deficiency; Male; Orotic Acid